DiaSorin S.p.A.

History

YearDetail
2000 The company was founded.
2007 The company was listed on Italian Stock Exchange.
2016 The company acquired Focus Diagnostic to enter molecular diagnostics sector in the U.S.
2018 The company partnered with Qiagen to test latent tuberculosis.
2020 The company made an agreement with TTP to develop Point-of-Care (POC) molecular solution.
2021 The company acquired Luminex Corp. for $1.8 billion.
2022 The company launched molecular reagents for the monkeypox virus.
  The company collaborated with BARDA  to support the clinical validation and FDA 510 authorization of LIAISON NES.